Shopping Cart
- Remove All
Your shopping cart is currently empty
ACT-1004-1239
🥰Excellent
Catalog No. T39665Cas No. 2178049-58-4
ACT-1004-1239 is an orally active, selective, and potent CXCR7 antagonist with immune-modulatory and myelin-promoting effects. It can be used to study inflammatory demyelinating diseases.
ACT-1004-1239
🥰Excellent
Catalog No. T39665Cas No. 2178049-58-4
ACT-1004-1239 is an orally active, selective, and potent CXCR7 antagonist with immune-modulatory and myelin-promoting effects. It can be used to study inflammatory demyelinating diseases.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $213 | In Stock | |
| 5 mg | $538 | In Stock | |
| 10 mg | $868 | In Stock | |
| 25 mg | $1,780 | In Stock | |
| 50 mg | $2,860 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "ACT-1004-1239"
Tannic acid
Cited
Gallotannic acid
T08011401-55-4
Tannic acid (Gallotannic acid) is a novel hERG channel blocker.
- $41
Size
QTY
CitedNicotinamide N-oxide
Nicotinamide-N-oxide, Nicotinamide 1-oxide, 1-oxynicotinamide
T06171986-81-8
Nicotinamide N-oxide (Nicotinamide 1-oxide) is recognized as an in vivo metabolite of nicotinamide which is a precurser of nicotinamide-adenine dinucleotide (NAD+) in animals. The enzyme that catalyzes the reduction of nicotinamide N-oxide to nicotinamide in the liver is xanthine oxidase.
- $33
Size
QTY
Artemotil Cited
β-Arteether, SM-227, Beta-Arteether, Arteether, (+)-Arteether
T332775887-54-6
Artemotil (SM-227) is a new, fast-acting antimalarial drug.
- $50
Size
QTY
CitedPlerixafor Cited
JM3100, AMD-3329, AMD 3100
T1776110078-46-1
Plerixafor (AMD-3329), a chemokine receptor antagonist, blocks the binding of stromal cell-derived factor (SDF-1alpha) to the cellular receptor CXCR4.
- $42
Size
QTY
CitedPlerixafor octahydrochloride Cited
SID791 octahydrochloride, Plerixafor 8HCl (AMD3100 8HCl), Plerixafor 8HCl, JM3100 octahydrochloride, JM 3100 8HCl, AMD 3100 octahydrochloride
T1776L155148-31-5
Plerixafor octahydrochloride (JM3100 octahydrochloride) blocks the binding of stromal cell-derived factor (SDF-1alpha) to the cellular receptor CXCR4, resulting in hematopoietic stem cell (HSC) release from bone marrow and HSC movement into the peripheral circulation. Plerixafor is a bicyclam with hematopoietic stem cell-mobilizing activity.
- $42
Size
QTY
CitedAZD8309
AZD-8309, AZD 8309
T25131333742-48-6In house
AZD8309 is a potent, orally available antagonist of the chemokine receptor CXCR2 that regulates neutrophil transport, significantly reduces MPO in the pancreas and lung, and decreases trypsin and elastase activity in the pancreas.AZD8309 can be used to study a range of inflammatory diseases.
- $129
Size
QTY
rac-NBI-74330
racNBI74330, rac NBI 74330
T26035473722-68-8In house
rac-NBI-74330 is an effective and selective CXCR3 antagonist.
- $88
Size
QTY
CXCR2-IN-1
T109051873376-49-8In house
CXCR2-IN-1 has a pIC50 of 9.3 and is a CXCR2 antagonist of the central nervous system penetration agent.
- $73
Size
QTY
SX-682
T84971648843-04-2
SX-682 is an orally available allosteric inhibitor of CXCR1 and CXCR2 that blocks tumor myeloid suppressor cell recruitment and enhances T cell activation and anti-tumor immunity, with the potential to treat castration-resistant prostate cancer.
- $34
Size
QTY
LIT927
LIT-927, LIT 927
T52072172879-52-4
LIT927 (LIT-927) is an orally active CXCL12 neutraligand (Ki: 267 nM for CXCL12 binding to CXCR4).
- $35
Size
QTY
CXCL-CXCR1/2-IN-1
T843252415653-55-1
CXCL-CXCR1/2-IN-1 is an orally active and potent inhibitor of the ELR+CXCL-CXCR1/2 pathway with anticancer and anti-angiogenic activity and can be used to study cardiovascular disease and cancer.
- $40
Size
QTY
Delmetacin
Demethacin
T6805216401-80-2In house
Delmetacin (Demethacin) is a non-steroidal anti-inflammatory compound with anti-inflammatory and analgesic activity and inhibitory effects on the CXC chemokine receptor CXCR1.
- $75
Size
QTY
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Chemical Properties
| Description | ACT-1004-1239 is an orally active, selective, and potent CXCR7 antagonist with immune-modulatory and myelin-promoting effects. It can be used to study inflammatory demyelinating diseases. |
| Targets&IC50 | CXCR7 (dog):2.3 nM, CXCR7 (human):3.2 nM |
| In vitro | ACT-1004-1239 inhibits CXCR7 in human, dog, rat, mouse, guinea pig and macaque with IC50s of 3.2, 2.3, 3.1, 2.3, 0.6 and 1.5 nM, respectively. [1] ACT-1004-1239 promotes the maturation of OPCs into myelin oligodendrocytes. [2] |
| In vivo | In a MOG-induced mouse model of EAE, ACT-1004-1239 treatment (10-100 mg/kg twice daily, orally) showed a significant dose-dependent reduction in the clinical score of the disease, leading to an increase in survival. At the highest dose tested (100 mg/kg twice daily), ACT-1004-1239 delayed disease onset and significantly reduced immune cell infiltration into the CNS and plasma filament light chain concentrations. [2] ACT-1004-1239 reduces pulmonary vascular permeability and reduces inflammatory cell infiltration. [3] |
| Molecular Weight | 522.55 |
| Formula | C27H28F2N6O3 |
| Cas No. | 2178049-58-4 |
| Smiles | N(C(=O)[C@@H]1[C@@H](NC(=O)C=2C=C(ON2)C3=C(F)C=C(F)C=C3)CCN(CC4CC4)C1)C5(CC5)C=6N=CC=CN6 |
Storage & Solubility Information
| Storage | keep away from moisture,store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||
| Solubility Information | DMSO: 5.00 mg/mL (9.57 mM), Sonication is recommended. | |||||||||||||||
Solution Preparation Table | ||||||||||||||||
DMSO
| ||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy ACT-1004-1239 | purchase ACT-1004-1239 | ACT-1004-1239 cost | order ACT-1004-1239 | ACT-1004-1239 chemical structure | ACT-1004-1239 in vivo | ACT-1004-1239 in vitro | ACT-1004-1239 formula | ACT-1004-1239 molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.